Skip to main content
NPCE logo

NeuroPace, Inc.

NPCENASDAQHealthcareMedical Devices

$12.78Today:- (-)1Y +20.11%

As of Oct 15, 2026 close

Market cap
$435.85M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$9.22$19.60
Volume (live)
-
Avg. volume (3M)
121.69K

NeuroPace (NPCE) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), NeuroPace used $11.01M of cash in operating activities and spent $332.00K on capital expenditures. That left free cash flow of −$11.34M. It repurchased $49.55M of its own shares.

NeuroPace Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for NeuroPace, Inc. (NPCE) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-21.47-27.14-32.96-47.08-36.08-24.28-29.97
Depreciation & Amortization1.951.771.612.990.300.310.42
Deferred Income Tax0.000.000.000.005.480.000.00
Stock Based Compensation11.0910.289.568.354.291.381.44
Change in Working Capital-4.01-5.45-2.48-4.790.37-2.070.01
Change in Accounts Receivable-1.83-0.54-4.85-0.391.30-2.38-0.75
Change in Inventory-3.67-2.42-1.70-2.13-1.160.67-1.64
Change in Accounts Payable-0.730.670.240.650.480.00-0.08
Change in Other Working Capital0.782.574.07-2.91-0.26-0.362.48
Other Operating Activities0.782.574.073.671.073.053.08
Net Cash from Operating Activities-11.01-17.95-19.70-36.87-24.58-21.61-25.03
Investing Activities
Capital Expenditures-0.33-0.31-0.17-0.60-0.38-0.06-0.47
Purchases of Investments0.009.300.000.00-85.01-17.01-18.02
Sales/Maturities of Investments0.009.3023.2024.400.006.3022.10
Other Investing Activities0.000.000.000.000.000.000.00
Net Cash from Investing Activities-0.338.9923.0323.80-85.40-10.773.62
Financing Activities
Debt Repayment-60.510.000.000.00-4.0924.4621.33
Common Stock Issued69.893.287.890.00109.090.000.00
Common Stock Repurchased-49.55-0.880.000.000.000.000.00
Other Financing Activities-0.54-0.88-0.560.49-2.4730.550.04
Net Cash from Financing Activities19.604.338.130.49102.5355.0121.37
Summary
Net Change in Cash8.26-4.6311.45-12.58-7.4522.63-0.04
Cash at Beginning of Period13.5518.186.7319.3126.764.124.16
Cash at End of Period21.8113.5518.186.7319.3126.764.12
Free Cash Flow-11.34-18.26-19.87-37.47-24.96-21.67-25.49
Supplemental Disclosures
Interest Paid-6.234.484.466.344.41-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About NeuroPace Cash Flow

What is NeuroPace's free cash flow?

NeuroPace had negative free cash flow of $11.34M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$11.01M minus $332.00K of capital expenditures.

How much does NeuroPace spend on capital expenditures?

NeuroPace spent $332.00K on capital expenditures in fiscal 2025, compared with $306.00K a year earlier.

Does NeuroPace pay dividends or buy back shares?

Yes. In fiscal 2025 NeuroPace returned $49.55M in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition